Showing results (501-510 of 630) with videos related to

Sort By:
Pageof 63
Nature Communications|October 25, 2024
The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trialsJonathan I Silverberg, David Rosmarin, Raj Chovatiya, et al.
Current Medical Research and Opinion|December 3, 2024
Use of advanced systemic therapy in patients with moderate-to-severe atopic dermatitis in the TARGET-DERM AD RegistryMichael A Haft, Keith D Knapp, Ami Claxton, et al.
Dermatology and Therapy|August 7, 2024
More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic DermatitisAndrew Blauvelt, Kilian Eyerich, Alan D Irvine, et al.
The Journal of Allergy and Clinical Immunology|December 2, 2019
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trialEmma Guttman-Yassky, Diamant Thaçi, Aileen L Pangan, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|February 19, 2025
Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD RegistryDawn Z Eichenfield, Keith D Knapp, Ami Claxton, et al.
Experimental Dermatology|May 18, 2021
Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe diseaseJonathan T Sims, Ching-Yun Chang, Richard E Higgs, et al.
Journal of the American Academy of Dermatology|May 18, 2025
Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitisRobert Bissonnette, Linda Stein Gold, Leon Kircik, et al.
American Journal of Clinical Dermatology|October 21, 2025
Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III TrialsTiffany Mayo, Jonathan I Silverberg, April Armstrong, et al.
The Journal of Allergy and Clinical Immunology|October 4, 2022
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studiesEmma Guttman-Yassky, Jacob P Thyssen, Jonathan I Silverberg, et al.
Dermatology and Therapy|June 23, 2025
Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)Emma Guttman-Yassky, Stephan Weidinger, Eric L Simpson, et al.
Pageof 63